Midazolam versus Fentanyl/Droperidol and Placebo as Intramuscular Premedicant

Publisher Website
Google Scholar
Abstract
Midazolam, a new short‐acting benzodiazepine with promising premedicant effects, was investigated in a double‐blind, randomized clinical trial in 203 patients versus fentanyl/droperidol and placebo. Subjective effects, side‐effects, amnesia and overall satisfaction were recorded. Midazolam caused the greatest decrease in anxiety level, and while causing more confusion and somnolence than placebo, caused less confusion and somnolence than fentanyl/droperidol. Half the patients who received midazolam reported anterograde amnesia. No serious side‐effects were reported. Patient satisfaction was greater in the midazolam group than in the other groups.

This publication has 12 references indexed in Scilit: